Published in Biologicals on February 24, 2011
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov (2012) 1.80
Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J (2012) 1.58
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J (2014) 1.22
Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J (2012) 1.05
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol (2015) 0.91
Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure. AAPS J (2012) 0.90
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood (2012) 0.88
Frontier of therapeutic antibody discovery: The challenges and how to face them. World J Biol Chem (2012) 0.88
Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development. MAbs (2016) 0.84
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol (2016) 0.83
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs (2013) 0.83
Design and engineering of deimmunized biotherapeutics. Curr Opin Struct Biol (2016) 0.82
Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. AAPS J (2012) 0.80
Aggregation, immune complexes and immunogenicity. MAbs (2011) 0.80
Safe anticoagulation when heart and lungs are "on vacation". Ann Transl Med (2015) 0.79
Early implementation of QbD in biopharmaceutical development: a practical example. Biomed Res Int (2015) 0.78
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol Appl Pharmacol (2016) 0.76
Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology? Clin Exp Allergy (2011) 0.76
Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation. J Immunol Res (2016) 0.76
Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms. J Pharm Sci (2016) 0.75
IgE immunotherapy against cancer. Curr Top Microbiol Immunol (2015) 0.75
Assessing the Immunogenicity of Biopharmaceuticals. BioDrugs (2016) 0.75
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Antimicrob Agents Chemother (2016) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99
Severe limb abnormalities after chorion villus sampling at 56-66 days' gestation. Lancet (1991) 4.48
All classes of intermediate filaments share a common antigenic determinant defined by a monoclonal antibody. Cell (1981) 4.28
Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol Lett (1985) 4.23
Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature (1991) 4.04
The hepatitis delta (delta) virus possesses a circular RNA. Nature (1986) 4.00
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost (2006) 3.56
Family management and deviant peer association as mediators of the impact of treatment condition on youth antisocial behavior. J Consult Clin Psychol (2000) 3.51
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol (2003) 3.25
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Universals and cultural differences in the judgments of facial expressions of emotion. J Pers Soc Psychol (1987) 3.22
Ultraviolet B and blood pressure. Lancet (1998) 2.83
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Monoclonal antibodies (McAbs) to determinants on human gamma chains: properties of antibodies showing subclass restriction or subclass specificity. Immunology (1982) 2.79
Predictors of repeated wheeze in the first year of life: the relative roles of cockroach, birth weight, acute lower respiratory illness, and maternal smoking. Am J Respir Crit Care Med (1999) 2.75
Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care (2000) 2.65
Charge-induced reversible strain in a metal. Science (2003) 2.55
Reconstitution of interleukin 2 with albumin for infusion. Lancet (1990) 2.37
The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. J Gen Virol (1986) 2.29
Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol (1990) 2.24
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med (1998) 2.14
False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost (2009) 2.14
Iodine and selenium deficiency associated with cretinism in northern Zaire. Am J Clin Nutr (1990) 2.14
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Preventive intervention for maltreated preschool children: impact on children's behavior, neuroendocrine activity, and foster parent functioning. J Am Acad Child Adolesc Psychiatry (2000) 2.13
The growing number of hemophilia registries: Quantity vs. quality. Clin Pharmacol Ther (2015) 2.04
A novel device to improve colon cleanliness during colonoscopy. Endoscopy (2012) 2.04
6-year experience of prenatal diagnosis in an unselected population in Oxford, UK. Lancet (1998) 2.04
A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2002) 2.03
Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy (2008) 1.97
Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet (1988) 1.95
Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem (1996) 1.93
Hepatitis A virus concentrations in immunoglobulin preparations. Lancet (1991) 1.92
Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88
Control of the development of iron-efficiency reactions in potato as a response to iron deficiency is located in the roots. Plant Physiol (1987) 1.87
Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther (2011) 1.86
Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell (1993) 1.82
Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet (2001) 1.80
A simple sensitive bioassay for interleukin-1 which is unresponsive to 10(3) U/ml of interleukin-2. J Immunol Methods (1987) 1.80
Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost (1998) 1.79
Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect (2003) 1.74
HTLV-1 infection in tropical spastic paraparesis: lymphocyte culture and serologic response. AIDS Res Hum Retroviruses (1988) 1.74
Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost (2009) 1.73
Prenatal determination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers. Lancet (1993) 1.71
Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays. Br J Haematol (1996) 1.67
[Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation]. Gesundheitswesen (2005) 1.65
Properties of monoclonal antibodies to human immunoglobulin kappa and lambda chains. Immunology (1981) 1.65
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol (2010) 1.65
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol (1995) 1.63
Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. J Immunol Methods (1985) 1.62
Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome. J Cell Biol (1998) 1.60
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis (2000) 1.58
Functional specialization of calreticulin domains. J Cell Biol (2001) 1.57
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther (2012) 1.57
Management and long-term follow-up of hepatic cysts. Am J Surg (2001) 1.57
Aspects of the molecular structure of IgG subclasses. Monogr Allergy (1986) 1.56
The effects of purified mitogenic proteins (Pa-1 and Pa-2) from pokeweed on human T and B lymphocytes in vitro. Clin Exp Immunol (1976) 1.56
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther (2014) 1.54
Hepatitis B virus antigens made in microbial cells immunise against viral infection. EMBO J (1984) 1.54
Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol (1997) 1.53
Localisation of the monocyte-binding region on human immunoglobulin G. Mol Immunol (1986) 1.52
Naturally occurring antibodies in human sera that react with the iron-regulated outer membrane proteins of Escherichia coli. Infect Immun (1985) 1.51
The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol (2001) 1.51
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost (2001) 1.50
Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med (2006) 1.49
IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost (2006) 1.49
Purification and characterization of the cytochrome b6 f complex from Chlamydomonas reinhardtii. J Biol Chem (1995) 1.48
Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem (2001) 1.48
Capsule endoscopy for the evaluation of patients with chronic abdominal pain. Endoscopy (2003) 1.48
Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology (1989) 1.47
Cloning and expression of the chromosomal immune interferon gene of the rat. EMBO J (1985) 1.47
Immunogenic and antigenic epitopes of immunoglobulins. XVII--Monoclonal antibodies reactive with common and restricted idiotopes to the heavy chain of human rheumatoid factors. Rheumatol Int (1986) 1.47
Effect of age on human neutrophil function. J Leukoc Biol (2000) 1.46
Surface-chemistry-driven actuation in nanoporous gold. Nat Mater (2008) 1.44
Expression of VHIII-associated cross-reactive idiotype on human B lymphocytes. Association with staphylococcal protein A binding and Staphylococcus aureus Cowan I stimulation. J Immunol (1991) 1.44
Relationship between the papain sensitivity of human gammaG immunoglobulins and their heavy chain subclass. Nature (1968) 1.44
Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol Rev (1998) 1.43
Conducting ecologically valid prevention research: recruiting and retaining a "whole village" in multimethod, multiagent studies. Am J Community Psychol (1997) 1.43
Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol (2001) 1.42
Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost (2005) 1.42
The loss of calretinin expression indicates aganglionosis in Hirschsprung's disease. J Clin Pathol (2004) 1.42
A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia. Infection (2006) 1.42
(E)-1-[4-(Methyl-sulfan-yl)phen-yl]-3-phenyl-prop-2-en-1-one. Acta Crystallogr Sect E Struct Rep Online (2008) 1.41
IgG4 as the predominant autoantibody in sera from patients with active state of pemphigus vulgaris. J Eur Acad Dermatol Venereol (2004) 1.41
Response of the potential of a gold electrode to elastic strain. Phys Chem Chem Phys (2009) 1.40
[Managed care in Germany: legal and economic aspects of its transferability]. Gesundheitswesen (1999) 1.40
Incidence of three cross-reactive idiotypes on human rheumatoid factor paraproteins. J Immunol (1988) 1.39
Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci U S A (1990) 1.39
[Pulmonary infection with Coccidioides immitis]. Ned Tijdschr Geneeskd (1996) 1.39
Universal leucocyte-depletion of blood components: cell concentrates and plasma. Vox Sang (2001) 1.39
[Indication for emergent revascularisation of acute carotid occlusion]. Chirurg (2007) 1.39
Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. J Clin Invest (1988) 1.38
Microbial contamination in four commercially available denture adhesives. J Prosthet Dent (1994) 1.38